Sistema Joins RDIF in Plan to Mass Produce Covid-19 Vaccine
Sistema, RDIF and Gamaleya institute are partnering on project
Clinical trials of the Russian vaccine will begin this month
(Bloomberg) – The Russian Direct Investment Fund is seeking to start mass production of a potential Covid-19 vaccine by fall at a site owned by billionaire Vladimir Evtushenkov’s Sistema PJSC.
RDIF, Sistema and the Gamaleya National Research Institute of Epidemiology and Microbiology, which is developing the vaccine, will start clinical testing this month and plan to begin production at Sistema’s Alium facility near Moscow, according to a joint statement Wednesday.
Russia has nearly half a million confirmed coronavirus cases, the third-most after the U.S. and Brazil. However, the authorities say the country is past the epidemic’s peak and have started to lift restrictions ahead of a July 1 referendum that could allow President Vladimir Putin to remain in power until 2036.